Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors

Temozolomide (TEM) as a single agent or in combination with capecitabine (CAPTEM) is active in well-differentiated advanced neuroendocrine tumors (NETs) of gastro-entero-pancreatic and thoracic origin. The predictive role of MGMT-promoter methylation in this setting is controversial. We sought to pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Brighi, Nicole, Lamberti, Giuseppe, Andrini, Elisa, Mosconi, Cristina, Manuzzi, Lisa, Donati, Giada, Lisotti, Andrea, Campana, Davide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955977/
https://www.ncbi.nlm.nih.gov/pubmed/36826067
http://dx.doi.org/10.3390/curroncol30020106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955977/
https://www.ncbi.nlm.nih.gov/pubmed/36826067
http://dx.doi.org/10.3390/curroncol30020106

Ejemplares similares